Jonathan Spicer MD PhD @DoctorJSpicer Twitter profile

Pinned Tweet

Jonathan Spicer MD PhD

1 year

As the thoracic surgeon on this team, here’s my view on this amazing effort: There is a world to discover in the geographic cellular relationships at play within a 1 mm2 section of tissue selected by a thoracic pathologist as the most representative area of lung cancer. @IASLC

Mark Sorin

@sorin_mark

1 year

Our paper is out in @Nature today! We resolved over 1.6 million cells from 416 lung cancer patients by imaging mass cytometry 😮! Buckle up…

14

25

157

3

0

55

Last Seen Profiles

@MtnShepherdess

@ConfluenciaCL

@TarqJ75

@Kekich_art

@samaberman

@bpatetas

@wyhnny

@Golf_Saudi

@kuromaru9

@Wack58

@abog

@MegMcLaughlinDA

@BokepLho29560

@brodaishola_

@TransAdvMadison

@NismoNollie

@doratwitteiraa

@cukienaknikmati

@GanjinZero

@Bintanghasibua8

@BokepLho29560

@vsadkovv

@namenea1306

@nodoubt

@BokepLho29560

@EinsteinSurfer

@stwmaniax

@remolabo

@PsychicHotbox

@IssaTetova

@Q20GG_

@Pzrge

@BokepLho29560

@3tr__52

@neverwazbroke

Jonathan Spicer MD PhD

@DoctorJSpicer

4 years

No joke - we had a patient swallow Lysol as a #disinfectant a couple of weeks ago to prevent COVID19 infection. He made it out of the hospital after his gastrectomy... This kind of nonsense is absolutely mind blowing.

627

3K

7K

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

Hard to believe but after 8 long years, the Spicer lab @RIMUHC1 finally has @CIHR_IRSC funding! Thank you to my amazing collaborators @DanielaQuail @loganawalsh @McGillGCI , Dr Morgan Craig @UMontreal . Never possible without the amazing stewardship of @ronirayes from the start!

10

9

140

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Hot stuff coming out in ⁦ @CellCellPress ⁩ on #neutrophils and #immunotherapy !

T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants

The eradication of antigenically heterogeneous tumors by T cell immunotherapies requires neutrophils.

www.cell.com

0

27

135

Jonathan Spicer MD PhD

@DoctorJSpicer

2 years

Here it is folks! #LCSM #AACR22

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer | NEJM

Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based neoadjuvant regimens have ...

www.nejm.org

6

34

137

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

Just like CM816, for those saying there is no OS effect, I ask you which curve do you prefer for your patients? Let’s just give it a bit of time, eh? @NEJM @ASCO @IASLC @AATSHQ @thoracic @ThoracicsCanada #ASCO23

10

19

103

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

Exciting list in the OR today! Case #1 : post-NeoADAURA stage IIA Case #2 : post-chemo+Nivo stage IIA Case #3 : post-NeoCOAST2 stage IIIA Thrilled to be operating with our fellow @bulgalucho ! @MThoracics @cusm_muhc @CodeVie_Life @CedarsCancer #LCSM

7

3

102

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

A beautiful lung cancer paper by @JonesDavid2013 and @MSK_Thoracic team! A key finding is that only 4% of metastatic lesions harbour actionable mutations not previously identified in the primary - an important argument for molecular testing in early stage!

Genomic mapping of metastatic organotropism in lung adenocarcinoma

Lengel et al. identify clinicopathological and genomic features of lung adenocarcinoma associated with the development of metastasis, metastatic burden, organotropism, and metastasis-free survival....

www.cell.com

2

26

90

Jonathan Spicer MD PhD

@DoctorJSpicer

9 months

#ALINA , #ADAURA and #KN671 were all smiles today @myESMO #ESMO23 ! Love these guys!

5

91

Jonathan Spicer MD PhD

@DoctorJSpicer

3 years

I’m pretty sure which arm I’d rather be in... #AACR21 #lcsm #tssmn

2

18

88

Jonathan Spicer MD PhD

@DoctorJSpicer

8 months

Next time you’re at tumour board discussing a stage III patient and debating between CRT+IO vs neoadj chemoIO+surgery, remember to ask both these questions:

3

16

88

Jonathan Spicer MD PhD

@DoctorJSpicer

2 years

I’m so excited about this news! Hard to believe that only 5 and half years since we recruited the first patient to this trial @cusm_muhc , we have an approved indication for #CM816 . This is amazing news for lung cancer patients in Canada! @LungCancer_Can @bmsnews @ThoracicsCanada

CancerNetwork®

@CancerNetwrk

2 years

Health Canada approved nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable non–small cell lung cancer prior to surgery. #NSCLC | @DoctorJSpicer

0

6

9

1

16

86

Jonathan Spicer MD PhD

@DoctorJSpicer

3 years

A huge thank you to @FRQS1 for extending my clinician scientist funding as Junior 2 recipient! Not possible without the support of my science mentor Dr. Morag Park @McGillGCRC and folks from @mcgillsurgery @lianefeldman and @LFerri123 and funding from @CodeVie_Life . #lcsm #tssmn

20

4

86

Jonathan Spicer MD PhD

@DoctorJSpicer

2 months

What an honour to have these two thoracic surgery luminaries come to @MThoracics @mcgillsurgery just 2 months apart! @BrendonStilesMD as our Flanders Lung Cancer visiting prof and @JonesDavid2013 as our Stikeman Cardiothoracic Surgery visiting prof. I loved my visits to

1

6

83

Jonathan Spicer MD PhD

@DoctorJSpicer

17 days

I hope the @IASLC and #LCSM community will find our team’s work useful! It was amazing to collaborate and learn from such a great group. There’s no doubt that this will have to become a living document with the incredible pace of development for patients with resectable NSCLC!

5

28

82

Jonathan Spicer MD PhD

@DoctorJSpicer

2 years

In case you’re in a rush, this is what you need to see and ask yourself which curve you’d rather be on. #LCSM #AACR22 @FordePatrick @nicogirardcurie

Jonathan Spicer MD PhD

@DoctorJSpicer

2 years

Here it is folks! #LCSM #AACR22

6

34

137

3

15

73

Jonathan Spicer MD PhD

@DoctorJSpicer

9 months

Finally, the first phase 3 trial in over a decade to show a statistically significant OS benefit in a non-biomarker selected population of resectable NSCLC pts. It’s been a long time coming! #LCSM @IASLC @myESMO @ASCOPost @AATSHQ @thoracic @ThoracicsCanada

Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in...

KEYTRUDA® (pembrolizumab) is the first anti-PD-1 therapy to demonstrate statistically significant improvement in OS as a neoadjuvant and adjuvant treatment versus pre-operative chemotherapy for NSCLC...

www.merck.com

0

16

71

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

What a MASSIVE accomplishment!!! Great news for patients. The Δ in lung function under represents the potential gains in QOL and reduction in therapeutic risk. Such a pivotal study that will guide treatment for a long long time to come! #LCSM ⁦ @NEJM ⁩

Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer | NEJM

The increased detection of small-sized peripheral non–small-cell lung cancer (NSCLC) has renewed interest in sublobar resection in lieu of lobectomy. We conducted a multicenter, noninferiority, pha...

www.nejm.org

5

14

69

Jonathan Spicer MD PhD

@DoctorJSpicer

2 years

For those interested, here’s a great summary of recent developments in lung cancer produced by @NEJMGroup under the fantastic editorial guidance of @jdoningtonmd #LCSM contributions from @AltorkiNasser @JulienMazieres @JPatelMD and many others!

0

24

65

Jonathan Spicer MD PhD

@DoctorJSpicer

2 months

Lovely work by Drs Cascone/⁦ @MARIANOPROVENCI ⁩ and colleagues adding to the now massive body of evidence supporting neoadj IO for patients with resectable NSCLC! This approach is the clear SoC for clinically evident stage II or III resectable NSCLC!

Perioperative Nivolumab in Resectable Lung Cancer | NEJM

Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Perioperative treatment (i.e., neoadj...

www.nejm.org

2

18

63

Jonathan Spicer MD PhD

@DoctorJSpicer

8 months

I can’t say enough about how important and useful a read this book is for anyone interested in understanding how we (humans) behave. Chapter 16 is particularly useful to understand why we end up in these perpetual conflicts. Also informative about how our interactions with social

10

4

64

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

What an unbelievable few days @ASCO and an incredible visit with the @HopkinsThoracic crew along with the neoadj intelligentsia with @MARIANOPROVENCI @CruzAPhD Drs Atocha Romero from @gecp_org and Tina Cascone from @MDAndersonNews , hosted by @FordePatrick ! Amazing inspiring fun!

2

59

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

Looks like we have another SoC option cooking for resectable lung cancer patients! #LCSM @IASCL @ASCO @myESMO @STS_CTsurgery @AATSHQ @ThoracicsCanada

Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in...

In pivotal study, KEYTRUDA® (pembrolizumab) in combination with chemotherapy before surgery and continuing as a single agent after surgery showed a statistically significant improvement in EFS versus...

www.merck.com

4

14

59

Jonathan Spicer MD PhD

@DoctorJSpicer

3 years

Finally! Real surgical data in #thoracic surgery for lung cancer. It’s been a long time coming: #LCSM #TSSMN

4

10

54

Jonathan Spicer MD PhD

@DoctorJSpicer

3 years

A few thoughts from our team @mcgillu @RIMUHC1 @McGillGCRC @cusm_muhc on the meaning of pathological complete response after neoadjuvant therapy for #lungcancer , kindly published by @TheLancetOncol #lcsm

Pathological complete response as a surrogate endpoint after neoadjuvant therapy for lung cancer

6 years have passed since Matthew Hellman and colleagues1 proposed major pathological response as a surrogate endpoint of survival for patients undergoing neoadjuvant therapy for operable lung...

www.thelancet.com

1

19

52

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

I hope we will put an end to whether Osi adds value for our patients. Having had more than one resected EGFR patient go on to craniotomy for symptomatic brain met after “curative” surgery I was sold on DFS, and confident that OS was just a matter of time!

Tagrisso demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant...

www.astrazeneca.com

7

8

51

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

Looking forward to a great session on therapy for early-stage lung cancer tomorrow morning here @ #TTLC23 with fantastic colleagues. This is an awesome meeting! But, I am struggling to figure out how to give a talk that doesn't discuss NEOadjuvant therapy... @IASLC

2

9

51

Jonathan Spicer MD PhD

@DoctorJSpicer

2 years

Adjuvant atezo in my mind is for incidental pathological stage II or III disease w/ PDL1>50% found post resection in patients fit enough to get adjuvant chemo. Patients with clinically evident stage II or III resectable disease should be oriented to neoadj chemo-nivo.

Sandip Patel MD

@PatelOncology

2 years

@DrewMoghanaki @DrJNaidoo @JackWestMD @OncoAlert @DasMillie11 The interim analysis for OS from IMP010 for PD-L1>50% is quite robust and we can have confidence in offering atezo here. For PD-L1 1-49% it’s not clear the benefit and I find CM816 with 3 cycles of chemo+nivo reasonable there as we await updated survival data

4

24

3

12

50

Jonathan Spicer MD PhD

@DoctorJSpicer

4 years

We are in the process of reformatting Julien’s proposal for a NET directed intervention in COVID19. Anyone keen on joining the effort please reach out! @jasonsknight @megeblad @TGOliver2 #NETs #neutrophils #COVID19 @JulienPottecher

Jason S Knight

@jasonsknight

4 years

🕸️✂️🤔 Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients

5

22

59

2

22

47

Jonathan Spicer MD PhD

@DoctorJSpicer

11 months

I’m sorry @nejm , but you are using the wrong terms. “PERI-OPERATIVE pembrolizumab has been shown to improve EVENT-FREE SURVIVAL in pts with RESECTABLE stage II-IIIB NSCLC!” This is NOT adjuvant therapy and the endpoint of the trial was NOT DFS! #LCSM

NEJM

@NEJM

11 months

Adjuvant therapy with the immune checkpoint inhibitor pembrolizumab has been shown to have a disease-free survival benefit in patients with early-stage non–small-cell lung cancer (NSCLC). Read the full KEYNOTE-671 trial Research Summary:

2

85

230

3

1

47

Jonathan Spicer MD PhD

@DoctorJSpicer

2 years

To all thoracic surgeons: Have faith in your #medonc colleagues and witness the impact of neoadj chemoIO on QOL! @STS_CTsurgery @AATSHQ @thoracic @ThoracicsCanada @EnriquetaFelip @SBroderickMD @BorisSepesi @maraantonoff @ekslim @BrendonStilesMD @ElliotServaisMD @ASCOPost @myESMO

2

3

46

Jonathan Spicer MD PhD

@DoctorJSpicer

10 months

Loved catching up with great friend and colleague, and amazing thoracic pathologist @pierrefiset in Singapore for #WCLC23 @IASLC ! Will need to get more of the @mcgillu @McGillGCI @RIMUHC1 out for the next @IASLC meeting.

1

46

Jonathan Spicer MD PhD

@DoctorJSpicer

9 months

Such a complete and well documented dataset! Amazingly clear and thorough presentation by Dr Cascone! Nice to see ph3 data with EFS analysis for multiN2 confirming what @MARIANOPROVENCI and @gecp_org taught us with NADIM1+2! @AATSHQ @STS_CTsurgery @thoracic @ThoracicsCanada

Patrick Forde

@FordePatrick

9 months

Outstanding presention of #CM77T by Dr. Tina Cascone at #ESMO23 ! EFS HR 0.58 strongly favors periop chemo-IO across PD-L1 strata, high pCR rate 25% (51%! in PDL1 high) and overall better surgical outcomes in chemo-IO arm. So #CM816 vs #CM77T vs #KN671 ? #LCSM

1

18

64

1

9

46

Jonathan Spicer MD PhD

@DoctorJSpicer

10 months

This is a very sad reality and I think it translates to a diminished understanding of the fundamentals of modern precision medicine amongst the average doctor because physician/surgeon scientists don’t just do discovery work, they educate and translate science to the clinic.

Albert Koong, MD PhD

@ACKoongMDPhD

10 months

Physician-scientists are a dying breed going from 4.7% in '80s to ~1.5% today. Multiple factors contribute including flat/declining #NIH funding. Translational research is critical for advancing clinical care.

21

142

404

2

5

46

Jonathan Spicer MD PhD

@DoctorJSpicer

10 months

In case anyone still had doubts about the potential benefits of IO for resectable #NSCLC , there’s another mountain of data coming our way! #LCSM @ASCOPost @myESMO @IASLC @AATSHQ @thoracic @ThoracicsCanada @STS_CTsurgery

Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemot...

CheckMate -77T represents the company’s second positive Phase 3 trial with an immunotherapy-based combination for the treatment of non-metastatic non-small cell lung cancer Positive results reinforce...

news.bms.com

1

8

45

Jonathan Spicer MD PhD

@DoctorJSpicer

4 years

One of the most important parts of our #thoracicsurgery fellowship is teaching the fellow to drive a tractor @SeverinSchmid @ThoracicsCanada #TSSMN

5

1

44

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

It’s for real folks! If you kill the tumor in the primary and lymph nodes, you’re killing it wherever else it might be. PCR after chemo-IO is a survival surrogate! Now we just need better measures of micromet disease to adjudicate neoadj more precisely. #elcc23 @IASLC

Dr Riyaz Shah

@DrRiyazShah

1 year

CM816; This is a killer slide. We already knew of the surgical outcome improvements thanks to @DoctorJSpicer . Not only does NAC+IO achieve that but look at the halving of distant recurrence and esp brain mets. Amazing. #ELCC23 .

1

11

33

2

11

43

Jonathan Spicer MD PhD

@DoctorJSpicer

3 years

Why was PFS sufficient to change practice for PACIFIC, but there's debate about whether DFS in surgical patients should be practice changing? #LCSM #TSSMN Is this surgical patient discrimination? #ASCO21

3

8

43

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

An excellent and pivotal study published by the @MDAndersonNews thoracic onc team! More evidence that these interminable 1 or 2 year courses of IO aren’t necessary to drive major EFS impact for early stage NSCLC. Here, only 4 cycles of Nivo did the trick!

Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung...

Compared with SABR alone, I-SABR significantly improved event-free survival at 4 years in people with early-stage treatment-naive or lung parenchymal recurrent node-negative NSCLC, with tolerable...

www.thelancet.com

0

13

44

Jonathan Spicer MD PhD

@DoctorJSpicer

1 month

Might I point out that the relevance of N2 positivity is eliminated when Nivo is in play. If you compare the green curves N2 vs non-N2 they are the same regardless of PCR status. Not so in pts treated with chemo alone. Hence, Nivolumab eliminates the TNM stage effects related to

Balazs Halmos

@DrSteveMartin

1 month

Dr. Cascone w intriguing update on CM77T focusing on nodal status Issue of downstaging is upstaged by key q - can data guide us tomorrow in clinic as to the adj component? IMO it can highlighting massive risk of recurrence in N2+ pts w nonpathCR and excellent HR here for IO arm

0

5

17

1

13

43

Jonathan Spicer MD PhD

@DoctorJSpicer

4 months

Are you excited to debrief and discuss all the early-stage lung cancer data that will be presented @AATSHQ and @ASCO ? Please register and attend our second annual Early stage Lung cancer International eXpert Retreat! #ELIXR24 We have a fantastic group of multi-disciplinary

2

11

42

Jonathan Spicer MD PhD

@DoctorJSpicer

3 months

I love this figure that @MHShahzad5 put together explaining the space, its opportunities, risks and challenges. Really nice description of the work ahead!

2

17

43

Jonathan Spicer MD PhD

@DoctorJSpicer

10 months

So excited about everything happening in the my lab these days! We had a tremendous meeting with some truly inspirational students. Couldn’t do this without all our collaborators and my science partner in crime @ronirayes ! Also featuring my dog Miller. He’s the best.

5

40

Jonathan Spicer MD PhD

@DoctorJSpicer

4 years

Very excited to see this published! 97% OS at 2 years for operable N2 disease. pCR 63%. If I have operable stage 3 N2 #lungcancer in 2020, I choochoochooooose this @DrewMoghanaki #lcsm #tssmn

1

9

41

Jonathan Spicer MD PhD

@DoctorJSpicer

1 month

Really important and not boring data presented by @marinagarassino showing that HRQoL is not impacted by the receipt of pembrolizumab in the KN671 trial. Sometimes a lack of difference is exactly what we hope to see!!! #ASCO24

Stephen V Liu, MD

@StephenVLiu

1 month

Engaging panel discussion at #ASCO24 on perioperative immunotherapy for NSCLC with Drs. Alberto Chiappori @dramycummings @marinagarassino @DoctorJSpicer John Heymach. Reported regimens more similar than different, which is reassuring.

1

8

14

1

10

42

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

Had an amazing tour of the @mcgillu @OslerLibrary with the always inspiring @dpardol1 and my thoracic surgery colleague @BorisSepesi . Dr Pardoll gave a masterclass on #immunotherapy and translational research @McGillGCI yesterday. More to come today at #ELIXR23 !!!

0

4

42

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

Arguably, this should have come out well before KN671 and speaks to the importance and value of academic trial groups and their ability to lead the way forward in cancer research! Congrats @MARIANOPROVENCI and the @gecp_org team!!!

Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer | NEJM

Approximately 20% of patients with non–small-cell lung cancer (NSCLC) receive a diagnosis of stage III disease. There is no current consensus regarding the most appropriate treatment for these pati...

www.nejm.org

1

12

41

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

As you prepare to watch @HwakeleeMD deliver the results of #KN671 @ASCO , let’s thank patients like Mr. Erkat who so bravely contributed to this trial effort and is back to work @CodeVie_Life keeping us safe as we care for patients! @CedarsCancer @cusm_muhc @RIMUHC1 #ASCO23

1

3

42

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

Here it is! @ASCO #ASCO23

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer | NEJM

Among patients with resectable early-stage non–small-cell lung cancer (NSCLC), a perioperative approach that includes both neoadjuvant and adjuvant immune checkpoint inhibition may provide benefit ...

www.nejm.org

1

12

41

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

So excited for #ELIXR23 , here in Montreal on June 16th and 17th! It's a packed agenda with international experts in thoracic oncology. It promises to be a great discussion with all the new data coming our way! Register here: #LCSM

1

13

40

Jonathan Spicer MD PhD

@DoctorJSpicer

4 years

If this doesn’t lead to implementation of such a sorely needed intervention, I don’t know what will! Let’s make lung cancer screening a reality with an equitable and regionalized approach! #lcsm

0

10

40

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

Interesting take from @EMA_News on CM816 limiting approval for pts with PDL1>1%! What shall we offer those patients with PDL1 neg tumors? Is this where folks will continue to use neoadj CRT? #LCSM . Can’t say I agree with cutting up such a small study.

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab)...

Recommendation based on results from the Phase 3 CheckMate -816 trial, in which Opdivo with chemotherapy demonstrated improved event-free survival and pathologic complete response compared to...

news.bms.com

6

11

40

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

This might be one of the most important figures from #KN671 @asco #ASCO23 - curious to hear people’s thoughts…

0

1

39

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

Here's a report from our team @RIMUHC1 @cusm_muhc @CedarsCancer led by @sorin_mark and supervised by @pierrefiset . NGS landscape for NSCLC at a population level in our publicly funded health care system in Quebec for the @mcgillu thoracic oncology network.

1

7

38

Jonathan Spicer MD PhD

@DoctorJSpicer

3 years

There you have it! <5 years from first recruited patient ⁦ @cusm_muhc ⁩⁩ we have evidence that this neoadjuvant regimen improves EFS! Hopefully data to come soon and subsequent approvals to usher in a new era for operable lung cancer patients! #lcsm

Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Event-Free Survival in...

CheckMate -816 is the first Phase 3 trial with an immunotherapy-based combination to demonstrate improved event-free survival and pathologic complete response in the neoadjuvant setting of non-small...

news.bms.com

0

8

39

Jonathan Spicer MD PhD

@DoctorJSpicer

7 months

Brilliant review of the metastatic EGFR space by @StephenVLiu ! Amazing to have one of the leading voices in lung cancer up here in Montreal for the #RESOT meeting!

0

5

37

Jonathan Spicer MD PhD

@DoctorJSpicer

4 months

Please check this out! It’s important to those interested in the management of resectable NSCLC! @IASLC @myESMO @ASCOPost @ThoracicsCanada @STS_CTsurgery @AATSHQ @thoracic

Mark Sorin

@sorin_mark

4 months

Our paper is out today @JAMAOnc ! We report a systematic review and meta-analysis of 43 studies related to neoadjuvant chemo-immunotherapy and chemotherapy involving 5431 patients with resectable NSCLC!

1

37

104

2

18

37

Jonathan Spicer MD PhD

@DoctorJSpicer

3 years

1/ Surgery for #lungcancer is not just one immovable and unchanging thing. We need NGS and molecular diagnostics before treatment decisions are made as much as possible. Surgery can and should be tailored to biology of disease. #LCSM #TSSMN

1

6

38

Jonathan Spicer MD PhD

@DoctorJSpicer

2 years

Say hello to next generation ypTNM derived from #CM816 in the form of % residual tumor volume (RVT) beautifully presented by Dr. Janice Taube from @HopkinsThoracic ! #LCSM @myESMO @IASLC

1

7

37

Jonathan Spicer MD PhD

@DoctorJSpicer

2 years

Very useful summary!

Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review...

Overall, neoadjuvant immunotherapy or chemoimmunotherapy is effective and safe in NSCLC. Compared with single-agent immunotherapy, neoadjuvant chemoimmunotherapy provides a significant improvement in...

pubmed.ncbi.nlm.nih.gov

0

13

37

Jonathan Spicer MD PhD

@DoctorJSpicer

3 years

Congratulations @JonathanCools !!! Well deserved and some great work to come from this brilliant surgeon scientist! @ThoracicsCanada @mcgillsurgery @MThoracics #tssmn @cusm_muhc @RIMUHC1

SSAT

@SSATNews

3 years

Congratulations Dr. Jonathan Cools-Lartigue for being named the SSAT 2021 recipient for the SSAT Career Development Award. #SSAT #AwardsCeremony

3

2

38

2

3

37

Jonathan Spicer MD PhD

@DoctorJSpicer

3 months

Have you faced a challenging decision for a case with stage II or III NSCLC? @jdoningtonmd and I would love to hear about it and discuss the challenges and possible solutions at our upcoming @peerview session @AATSHQ #AATS24 ! Submit your case for discussion here:

PeerView

@PeerView

3 months

Submit your resectable #LungCancer cases for Drs. Jessica Donington ( @jdoningtonmd ) & Jonathan Spicer ( @DoctorJSpicer ) to discuss during a live symposium on #perioperative #immunotherapy during #AATS2024 on April 27 at 12:00 PM EDT #MedEd #MedTwitter

0

7

8

0

21

37

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

So excited to learn from remarkable surgeons @paugalde20 @BrighamThoracic and @sara_najmeh @MThoracics @mcgillsurgery about their strategies for locally advanced resectable NSCLC @AATSHQ this weekend! It will be a superb program! @ThoracicsCanada @thoracic @WomenInThoracic

PeerView

@PeerView

1 year

Register ASAP to meet expert @DoctorJSpicer , @sara_najmeh , & Dr. Figueroa in Los Angeles during #AATS2023 ! A Live #MedEd Symposium on #NSCLC #Immunotherapy treatment options will be taking place on Saturday, 5/6 at 12:00 PM PDT. See you there! #MedTwitter

0

7

13

1

14

36

Jonathan Spicer MD PhD

@DoctorJSpicer

9 months

How does statistically significant OS change your perspective on neoadjuvant strategies for patients with resectable NSCLC? #LCSM

Jonathan Spicer MD PhD

@DoctorJSpicer

9 months

Finally, the first phase 3 trial in over a decade to show a statistically significant OS benefit in a non-biomarker selected population of resectable NSCLC pts. It’s been a long time coming! #LCSM @IASLC @myESMO @ASCOPost @AATSHQ @thoracic @ThoracicsCanada

0

16

71

4

10

35

Jonathan Spicer MD PhD

@DoctorJSpicer

2 years

Almost 5 years to day after the first patient in CM816 was recruited @mcgillu @cusm_muhc we have a new indication that will dramatically change the lives of patients with locally advanced operable lung cancer! Can’t wait to see what people think of the PCR/EFS correlations #LCSM

1

2

35

Jonathan Spicer MD PhD

@DoctorJSpicer

4 years

A critical first step towards making immunotherapy an integral part of operable #lungcancer ! Proud to have been one of the top recruiters to this pivotal trial ⁦ @cusm_muhc ⁩ ⁦ @RIMUHC1 ⁩ ⁦ @CedarsCancer ⁩ ⁦ @CodeVie_Life ⁦ #lcsm #tssnn

Opdivo (nivolumab) Plus Chemotherapy Shows Statistically Significant Improvement in Pathologic...

CheckMate -816 met a primary endpoint of improved pathologic complete response in patients who received Opdivo plus chemotherapy before surgery Positive results mark the first time an immune checkp...

news.bms.com

0

7

35

Jonathan Spicer MD PhD

@DoctorJSpicer

4 years

Great summary of things to come

1

8

35

Jonathan Spicer MD PhD

@DoctorJSpicer

8 months

This was a very important and unique study showing that multi-center platform neoadjuvant studies are feasible in resectable lung cancer and are capable of generating interesting translational science! More to come as NeoCOAST2 is rapidly accruing…

Cancer Discovery

@CD_AACR

8 months

November issue— Neoadjuvant Durvalumab Alone or Combined with Novel #ImmunoOncology Agents in Resectable #LungCancer : The Phase 2 NeoCOAST Platform Trial, by Tina Cascone, @FordePatrick et al. @MDAndersonNews @bloombergkimmel @HopkinsKimmel #Immunotherapy

0

7

14

0

10

34

Jonathan Spicer MD PhD

@DoctorJSpicer

1 month

What a #ESTS24 for @filippog92 here in beautiful Barcelona! Winner of the @thoracic Young Investigator Award for his work on ALK re-arranged resected NSCLC! Love these trans-Atlantic collaborations!

Jonathan Spicer MD PhD

@DoctorJSpicer

1 month

So proud of @filippog92 and his work with our team @MThoracics . These data are so impactful to how we should think of ALK rearranged disease which is so frequently a systemic condition even when thought to be clinical stage I. Proof that understanding the biology of the disease

1

5

25

2

33

Jonathan Spicer MD PhD

@DoctorJSpicer

2 years

The goal is pCR @AACR ! @nicogirardcurie @PatEibenberger

1

7

34

Jonathan Spicer MD PhD

@DoctorJSpicer

2 months

The @MThoracics Stikeman Visiting Professorship in Cardio-Thoracic Surgery is the oldest such event in North America and is relatively unique in its mission to reunite the alumni of this amazing training environment! Thank you to the generous enduring support of the Stikeman

0

3

33

Jonathan Spicer MD PhD

@DoctorJSpicer

2 years

Interested in #Neutrophil Extracellular Traps and #Cancer ? Here's a really excellent review written by our own brilliant and recently @FRQS1 funded PhD student @MeghanDeMeo ! @RIMUHC1 @McGillGCI

3

9

34

Jonathan Spicer MD PhD

@DoctorJSpicer

3 years

It was a privilege to share these results with the #ASCO21 and #LCSM community. The surgical team for CM816 has a lot to be proud of for these findings and for having taken on this daunting challenge.

Surgical Outcome Data Reported for CheckMate-816

Additional data from the CheckMate-816 trial indicate that neoadjuvant administration of the PD-1–blocking antibody nivolumab combined with chemotherapy is a potential treatment in resectable...

dailynews.ascopubs.org

0

9

34

Jonathan Spicer MD PhD

@DoctorJSpicer

5 months

This is a remarkable finding!!!

Science Translational Medicine

@ScienceTM

5 months

Transplants of lung progenitor cells are safe in people with #COPD and show early signs of improving lung function and exercise capacity, according to results from a clinical trial involving patients with various stages of the disorder. #TongjiUniversity

0

20

54

1

9

33

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

Oh man! I am so excited to finally be able to talk about this remarkable study led by amazing friend and outstanding scientist @loganawalsh from @McGillGCI , nearly 5 years in the making! This brilliant work of science has key implications for translation to lung cancer patients!

Logan Walsh

@loganawalsh

1 year

Grateful to AMAZING co-corresponding authors @PJoubertPatho Peter Siegel & (on both studies) TME aficionado @danielaquail - & collaborators Marie-Christine Guiot, Kevin Petrecca, @LeilaAkkari1 @DoctorJSpicer @pierrefiset @IanWatsonLab @Parklabmcgillu & many more not on twitter 🙏

6

2

26

1

3

33

Jonathan Spicer MD PhD

@DoctorJSpicer

2 years

If you’re interested in how #neutrophil extracellular traps play a role in cancer progression and metastasis, have a look at this excellent review by our very own brilliant PhD student @MeghanDeMeo @RIMUHC1 @cusm_muhc @mcgillu

2

5

32

Jonathan Spicer MD PhD

@DoctorJSpicer

10 months

Excited to see the fate of surgery for mesothelioma today with @ekslim and @paugalde20 @IASLC #WCLC23 ! Since starting my practice, these are some of the hardest conversations to have with patients. @CDNCancerTrials @ThoracicsCanada @AATSHQ @STS_CTsurgery @thoracic @myESMO @ASCO

1

5

32

Jonathan Spicer MD PhD

@DoctorJSpicer

2 years

If you’re going to @AATSHQ this coming weekend, don’t miss this amazing lunch session where I will be discussing all aspects of peri-operative therapy for operable lung cancer with the illustrious @AltorkiNasser ! #TSSMN #LCSM

Kadrin Wilfong, MD

@KadrinWilfong

2 years

@cQIme @WomenInThoracic @mghctsurgery @BrighamThoracic @TSRA_official @WCM_CTSurgery @DukeCTSurgery @UVA_TCV_Surgery @UMichCTSurgery @yalectsurgery With @AltorkiNasser & @DoctorJSpicer as faculty & focus on practice-changing advances in perioperative immunotherapy, it's sure to be among the most exciting sessions at #AATS2022 ! Get answers to all your questions + lunch provided. Pre-reg via @PeerView

0

9

13

0

11

32

Jonathan Spicer MD PhD

@DoctorJSpicer

7 months

Have a look at our product from #ELIXR23 to generate a Canadian consensus approach to resectable early-stage #NSCLC . An effort led by my amazing colleague @NormandBlais from @chumontreal and our remarkable alumnus thoracic surgery fellow @JamieTankel from @MThoracics @cusm_muhc !

James Tankel

@JamieTankel

7 months

Proud to share my most recent and important publication to date. Under the amazing guidance of @NormandBlais and @DoctorJSpicer ....transcanadian guidelines for Mx of stage II / III NSCLC!!

5

4

29

1

6

32

Jonathan Spicer MD PhD

@DoctorJSpicer

29 days

I'm honestly blown away by the world-class faculty we've been able to recruit to Montreal for this exciting meeting! #ELIXR24 Not too late to register and attend! Old Montreal is lovely in the summer: @NormandBlais @ValsamoA @maraantonoff @drcheema_cancer

Waël Hanna

@wc_hanna

29 days

Looking forward to speaking and reconnecting with colleagues at #ELIXR24 Montreal! Have a look at the program of events here:

0

2

3

1

15

32

Jonathan Spicer MD PhD

@DoctorJSpicer

4 months

It’s a nice piece @JamieTankel - your writing is always on point. However, I’m sorry to say that the surgical obsession with lymph nodes for cancer operations seems more related to this act as a differentiating factor compared to other therapeutic modalities or other surgeons

James Tankel

@JamieTankel

4 months

Great opportunity to write a piece with the amazing @OryWiesel ... relationship between surgeon experience and lymph node yield after surgery for NSCLC? I think there is more than meets the eye.... @DoctorJSpicer @JonathanCools @LFerri123

0

3

8

2

9

31

Jonathan Spicer MD PhD

@DoctorJSpicer

10 months

So proud to be part of this effort led by Dr Tina Cascone and @FordePatrick ! This is a first in kind study in #NSCLC proving that a platform approach is an efficient design to select promising agents in the neoadjuvant window. Amazing team effort! #LCSM

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung...

NeoCOAST, the first neoadjuvant platform trial of novel immuno-oncology combinations, demonstrates that combined therapies improve responses and immunologic cell activation compared to durvalumab...

aacrjournals.org

0

7

29

Jonathan Spicer MD PhD

@DoctorJSpicer

1 month

I am so impressed with the remarkable commitment to high quality educational content coming from @ASCO leadership. Amazing work from our team captain @RManochakian who put a tremendous amount of energy into bringing @HenryParkMD @Dingemans_AnneM and I towards content that is

Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation

@RManochakian

1 month

🚨🔥 @ASCO #ASCO24 @OncoAlert Inviting #LCSM colleagues to: ✅A Case-Based #EducationSession , I’m honored to chair, joined by great experts/colleagues: @DoctorJSpicer @HenryParkMD @Dingemans_AnneM on: Locally Advanced Non-Small Cell #LungCancer ⏰Sun, June 2 at 11:30 📍Hall D1

3

8

40

3

6

31

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

Come hear a diversity of perspectives on the approach to locally advanced lung cancer @AATSHQ with our @PeerView session. Learn from brilliant surgeons @paugalde20 and @sara_najmeh how to manage some complex cases and I’ll be sharing the latest data in context! #AATS2023

0

13

31

Jonathan Spicer MD PhD

@DoctorJSpicer

3 years

Join now for results of Checkmate 816 phase 3 results for operable NSCLC! #AACR21 @FordePatrick #lcsm #tssmn

0

3

31

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

Evolutionary characterization of lung adenocarcinoma morphology in TRACERx | Nature Medicine. Amazing stuff!!! #LCSM

Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

Nature Medicine - Analyses of the TRACERx study unveil the relationship between tissue morphology, the underlying evolutionary genomic landscape, and clinical and anatomical relapse risk of lung...

www.nature.com

1

9

31

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

Excited to announce our post-doc fellowship in clinical/translational thoracic oncology research with our multi-D team @cusm_muhc @RIMUHC1 . Looking for MDs from #surgery , #medonc , #pulmonary , #pathology or #radonc , or PhDs with interest in clinical research. Please DM! #LCSM

1

11

31

Jonathan Spicer MD PhD

@DoctorJSpicer

10 months

Great session on the new frontiers for the treatment of mesothelioma @ThoracicsCanada featuring talks by @IsaOpitz , @CherylHoMD1 and Dr Marc De Perrot. Lots of key nuance brought to the interpretation of #MARS2 recently presented by @ekslim @IASLC #WCLC23 .

2

5

31

Jonathan Spicer MD PhD

@DoctorJSpicer

3 years

Join us Sunday for a great line up of presentations on #lungcancer @ASCO , including these results, which I think are pretty cool! #lcsm @FordePatrick @SBroderickMD @JulieBrahmer @MARIANOPROVENCI @DrMarkAwad @t_mitsudomi @EnriquetaFelip #ASCO21

Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet...

8503 Background: CheckMate 816 (NCT02998528) is a randomized phase 3 study of neoadjuvant NIVO + chemo vs chemo in resectable NSCLC. The study met its first primary endpoint, demonstrating signific...

ascopubs.org

1

10

30

Jonathan Spicer MD PhD

@DoctorJSpicer

11 months

Dr D’Amico @DukeCTSurgery explaining some little known important facts about “R uncertain” status and encouraging us all to be better surgeons. It’s not about tools, but rather about the surgeon’s mindset going into each operation. “It’s not the incisions, it’s the surgeon!”

2

5

30

Jonathan Spicer MD PhD

@DoctorJSpicer

4 years

From the surgeon who saved that man’s life. We sincerely hope that the insane suggestions made by #potus don’t influence anyone to try something so incredibly harmful. @ThoracicsCanada @mcgillsurgery

Lorenzo Ferri MD PhD

@LFerri123

4 years

So this is what Lysol does to your stomach if you follow the advice of #Trump #POTUS and take it internally. Can someone please prevent this man from spewing false advice and dangerous rumours?

2

37

53

0

7

30

Jonathan Spicer MD PhD

@DoctorJSpicer

4 years

Thrilled to be gaining Dr Sara Najmeh as a colleague back in the North very soon! We are so very excited to have you back @mcgill ! A true superstar indeed! @CodeVie_Life @cusm_muhc @MThoracics @mcgillsurgery @DukeCTSurgery @sara_najmeh @RIMUHC1 @ThoracicsCanada

Jacob Niall Schroder

@JacobNiall

4 years

It was easy to train such a super star!

0

1

12

2

1

30

Jonathan Spicer MD PhD

@DoctorJSpicer

2 years

CheckMate 816: Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC - The ASCO Post

CheckMate 816: Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC

As reported in The New England Journal of Medicine by Forde et al, the phase III CheckMate 816 trial has shown improved pathologic complete response rate and event-free survival with the addition of...

ascopost.com

0

6

29

Jonathan Spicer MD PhD

@DoctorJSpicer

2 years

So proud of @MiletteSimon ’s work in our lab with @DanielaQuail ! Congratulations! Hopefully, folks will get to read about your important discoveries before too long! @gcss_gci @McGillGCI @CIHR_IRSC @RIMUHC1 @crp_tc

0

2

28

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

If you couldn’t make it to Montreal and because this event sold out so quickly, #ELIXR23 will be livestreamed June 16th and 17th! We have an amazing lineup of speakers talking about exciting stuff! Livestream link: Program link:

2

10

29

Jonathan Spicer MD PhD

@DoctorJSpicer

5 years

Effect of Exercise and Nutrition Prehabilitation on Functional Capacity in Esophagogastric Cancer Surgery: A Randomized Clinical Trial. | Esophageal Cancer | JAMA Surgery | JAMA Network

Effect of Prehabilitation on Functional Capacity in Esophagogastric Cancer Surgery

This randomized clinical trial investigates the effect of an exercise and nutrition conditioning program (prehabilitation) vs usual care on functional capacity in patients undergoing esophagogastric...

jamanetwork.com

1

13

28

Jonathan Spicer MD PhD

@DoctorJSpicer

3 months

This went a bit under the radar, but important data from #ELCC24 from the 77T periop Nivo trial. Nice demonstration of impact on QoL that includes the entire therapeutic trajectory! Important improvement in time to definitive deterioration. @IASLC @myESMO

0

8

29

Jonathan Spicer MD PhD

@DoctorJSpicer

2 years

While trials bring scientific progress to patients, I get so energized by our brilliant students who are working on the next big thing! Love our labs meetings with @DanielaQuail and @loganawalsh @McGillGCI and @RIMUHC1 . Great presentations by @MeghanDeMeo and @LyndonCWalsh today!

1

3

28

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

This is a nice real-world validation of the findings from of a classic 🇨🇦 @CDNCancerTrials study BR10. Also, fantastic meeting for #thoracic #surgeons and their families! #GTSC23

Jorge Humberto Rodríguez Quintero M.D.

@huroqu90

1 year

Having a blast in the @GenThorSurgClub presenting our study on adjuvant systemic therapy underutilization for stage Ib NSClC! One of the best meetings to attend! @BrendonStilesMD @nchudgar @MontefioreSurg @MontefioreCTS #GTSC23

1

3

24

1

0

28

Jonathan Spicer MD PhD

@DoctorJSpicer

1 year

@DrewMoghanaki Sorry, but I disagree. @gecp_org is the only academic group to have completed a randomized trial in the peri-operative immunotherapy resectable NSCLC space. Hence, the only group with the ability to conduct unbiased science in this space and that's a big deal. Very @NEJM worthy!

1

3

27